MYLAN INC.
Healthcare · Pharmaceutical Preparations · PA · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY14 | FY13 | FY12 | FY11 | FY10 | FY09 | |
|---|---|---|---|---|---|---|
| Revenue | $1.72B | $1.63B | $6.80B | $6.13B | $5.45B | $5.09B |
| Operating income | $1.35B | $1.14B | $1.11B | $1.01B | $721.6M | $523.4M |
| Net income | $116.6M | $107.5M | $640.9M | $536.8M | $345.1M | $232.6M |
| Total assets | $15.89B | $15.29B | $11.93B | $11.60B | $11.54B | $10.80B |
| Total liabilities | $12.61B | $12.33B | $8.58B | $8.09B | $7.92B | $7.66B |
| Equity | $3.28B | $2.96B | $3.36B | $5.39B | $5.17B | $4.71B |
| EPS (diluted) | $0.29 | $0.27 | $1.52 | $0.23 | $0.20 | $0.30 |
| Shares out. | 371.9M | 395.6M | 426.9M | 437.1M | 329.0M | 306.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2014- Operating margin
- 78.8%
- Net margin
- 6.8%
- Return on equity
- 3.6%
- Return on assets
- 0.7%
- Return on capital (ROCE)
- 12.8%
- Liabilities / assets
- 79.4%
- Debt / equity
- 3.85×
- Book value / share
- $8.81
- Revenue growth (YoY)
- 5.2%
- Net income growth (YoY)
- 8.5%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2014- Altman Z″ (distress)
- 2.20grey zone
- Accruals / assets
- −5.7%clean
- Piotroski F-Score
- 8/9strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 warning● 4 good- High leverage (liabilities > 70% of assets)
- Altman Z″ in the grey zone
- Operating margin is positive
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
FDA-approved drugs
openFDA · most recent- APREPITANTMar 5, 2026
- MACITENTANDec 3, 2025
- LINAGLIPTINNov 3, 2025
- PACLITAXELAug 19, 2025
- EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATEMay 20, 2025
- DABIGATRAN ETEXILATE MESYLATEFeb 3, 2025
- ARIPIPRAZOLEDec 3, 2024
- SUCRALFATESep 12, 2022
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 2Recruitingreadout ~2026-11-30Investigating Ovulation Inhibition for Use as a Contraceptive
- Phase 3Active Not Recruitingreadout ~2027-05Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Bresch Heather MOfficer — Chief Executive Officer | Feb 27, 2015 | D | 544,727 | — |
| Lyons Dillon JoellenDirector | Feb 27, 2015 | D | 3,609 | — |
| Cindrich Robert JDirector | Feb 27, 2015 | D | 8,135 | — |
| Piatt Rodney LDirector | Feb 27, 2015 | D | 33,135 | — |
| Dimick Neil FDirector | Feb 27, 2015 | D | 38,587 | — |
| Sheehan John DOfficer — EVP and CFO | Feb 27, 2015 | D | 138,318 | — |
| Leech Douglas JDirector | Feb 25, 2015 | Gift | 2,120 | $0.00 |
| Vanderveen Randall LDirector | Feb 27, 2015 | D | 35,787 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Results of operationsMar 2, 2015
- Entered a material agreement · Completed an acquisition or disposition · New financial obligation · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Other material eventFeb 27, 2015
- Entered a material agreement · Terminated a material agreement · New financial obligationJan 30, 2015
- Shareholder vote · Other material eventJan 29, 2015
- Other material eventJan 28, 2015
- Other material eventJan 14, 2015
- Entered a material agreement · Terminated a material agreement · New financial obligationDec 29, 2014
- Director / officer change · Other material eventNov 5, 2014
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- S-3ASRMay 8, 2025
- S-3ASRMay 6, 2022
- EFFECTSep 28, 2021
- 424B3Sep 28, 2021
- UPLOADSep 17, 2021
- S-4FORM S-4Sep 10, 2021
- EFFECTDec 11, 2018
- 424B3FORM 424B3Dec 11, 2018
- CORRESPDec 7, 2018
- UPLOADNov 20, 2018
- S-4Nov 9, 2018
- 424B3Jan 3, 2017
- 424B3Jan 3, 2017
- CORRESPDec 29, 2016
- S-4/AS-4/AMENDMENT NO. 1Dec 22, 2016
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.